Lonza, BioWa Sign Licensing Agreement - - BioPharm International

ADVERTISEMENT

Lonza, BioWa Sign Licensing Agreement



BioWa and Lonza have entered into a licensing agreement with MedImmune, the global biologics research and development arm of AstraZeneca, under which  MedImmune has licensed the companies’ Potelligent CHOK1SV cell line technology for use in multiple proprietary antibodies in its pipeline.

Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System.  The GS System includes Lonza’s host cell line, CHOK1SV.  Potelligent Technology is designed to improve the potency and efficacy of therapeutic antibodies by improving antibody-dependent cellular cytotoxicity (ADCC), one of the major mechanisms of therapeutic antibodies.

MedImmune entered into a previous licensing agreement with BioWa in 2007 for Potelligent Technology.   Today’s agreement incorporates Lonza’s technology to the existing Potelligent Technology.

Source: Lonza

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here